Medical Science Liaison- Immunology

Medical Science Liaison

Join us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. Argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to treat patients across dozens of severe autoimmune diseases.

We are building a new kind of biotech company, one that maintains its roots as a science-based start-up and pushes our commitment to innovate across all corners of our business. We strive to inspire and grow our company, our partnerships, our science, and our people, because when we do, we deliver more for patients.

Vision 2030 is our long-term commitment to transform the treatment of autoimmune diseases by strengthening our leadership in neonatal Fc receptor (FcRn) biology, investing in our continuous pipeline of differentiated antibody candidates, and scaling in a disciplined way to ensure innovation remains core to the argenx mission. 'Vision 2030' includes the following goals: 50,000 patients globally on treatment with an argenx medicine, 10 labeled indications across all approved assets, including VYVGART and potentially empasiprubart and ARGX-119 and five new molecules in Phase 3 development.

The Medical Science Liaison (MSL), a field-based extension of the Medical Affairs team, is an expert on argenx's scientific data, products and trials, and is responsible for engagement with Key Opinion Leaders at academic and community centers, including potential and confirmed clinical research sites.

The MSL will represent and reflect argenx's values as a science-driven, patient-centric organization developing innovative medicines for patients and always upholding the highest ethical standards.

The MSL will support KOL development and advocacy while serving as a strategic field partner with cross-functional colleagues.

The MSL is critical in understanding the management of diseases of interest, mapping the patient journey, identifying unmet medical needs and data gaps and gathering and sharing insights to enhance patient care.

The MSL will identify clinical trial sites and opportunities for research, work closely with clinical development colleagues to coordinate with external stakeholders, support execution of clinical studies and build productive collaborations.

This position is remote and will cover the following territory: Expert medical resource and argenx ambassador

Develop and continuously maintain the highest scientific and medical expertise of all relevant diseases, products, development plans, and be acknowledged internally and externally as an expert

Identify and develop productive collaborations with Key Opinion Leaders, other important customers and stakeholders, including professional organizations

Support the development and implementation Strategic Territory Plans to advance Medical Affairs strategy

Maintain a high level of knowledge of and appropriately implement current local pharmaceutical regulation and ensure implementation of argenx policies and procedures

Scientific/medical exchange and education, and insight generation

Ensure timely and informative scientific/medical exchanges with external stakeholders that accurately reflect scientific data and research objectives

Deliver high quality scientific/medical education in a variety of settings, including related to disease states of interest, clinical studies, investigational products and obtain valuable insights that can be disseminated throughout the organization

Implement Medical Affairs tactics to assess potential new indications, including the treating community, patient pathways, diagnostic practices and management

Coordinate the timely and appropriate response to external Medical Information enquires

Identify potential high-impact medical research projects and publication opportunities, in line with argenx identified areas of interest

Attend appropriate local, national, and international meetings and congresses to gather intelligence, develop productive collaborations, assist personal education, ensuring insights are shared within argenx

Ensure all external interactions are conducted in accordance with argenx objectives, compliance policies and procedures as well as with established legal and ethical standards

In collaboration with argenx clinical development and operations teams:

Identify potential investigators and centers for participation in clinical research, support feasibility assessments and site initiation, and develop and maintain productive collaborations

Conduct training with CRO, CRAs and study site staff as required

Develop and execute the optimal site contact plan ensuring to build and maintain productive collaborations with sites to support clinical research and KOL development and advocacy,

Support the resolution of study issues at a site level

Escalate any safety reports consistent with argenx policy

The MSL is not responsible for advising sites about detailed study specific procedures or making decisions about clinical study operational issues and should refer these to the relevant colleagues

Ensure a close working relationship with all argenx functions, including cross-functional field partners

Support cross-functional teams to ensure operations are patient-focused, including rapidly responding to internal and external requests to discuss specific situations and challenges and provide medical affairs support to all stakeholders

Ability to quickly understand complex disease areas, treatments and clinical development plans, healthcare landscape, hospital systems, healthcare professionals, and patient journey

Demonstrated ability to build productive collaborations with medical experts

Scientific, healthcare or medical degree (PharmD, PhD, MD, DO, DNP, PA)

• 3+ years field-based experience in biopharmaceutical industry
• Experience in clinical R&D and/or medical affairs preferred
• Clinical experience in neurology, hematology, immunology, and/or rare diseases is an advantage
• Ability for 50% travel